SCHEMBL7092773

SCHEMBL7092773

NC(c1ccccc1)[C@@H](NS(=O)(=O)c1ccc(F)cc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 3/20 0.51
SLC1A2 P43004 3/20 0.51
SLC1A1 P43005 3/20 0.51
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TAAR1 Q96RJ0 1/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
MMP13 P45452 2/20 0.43
GBA1 P04062 2/20 0.43
MMP3 P08254 1/20 0.43
MMP7 P09237 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
MMP8 P22894 1/20 0.42
ALDH1A1 P00352 1/20 0.41
FFAR1 O14842 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7092490 1.00 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1KMT2A
SCHEMBL7092770 1.00 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1KMT2A
SCHEMBL7618216 1.00 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1KMT2A
SCHEMBL7618209 1.00 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1KMT2A
SCHEMBL7092491 0.98 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1MEN1KMT2A
SCHEMBL2067895 0.89 GBA1 (0.51) SLC1A3SLC1A2SLC1A1KEAP1MMP1
SCHEMBL3862569 0.89 GBA1 (0.51) SLC1A3SLC1A2SLC1A1KEAP1MMP1
SCHEMBL3852094 0.89 GBA1 (0.51) SLC1A3SLC1A2SLC1A1KEAP1MMP1
SCHEMBL7089076 0.87 GBA1 (0.50) SLC1A3SLC1A2SLC1A1KEAP1MMP1
P-Cymene SCHEMBL7517875 0.87 ALDH1A1 (0.46) SLC1A3SLC1A2SLC1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225289-A1 Process for the preparation of tricyclic amino alcohol derivatives ASAHI KASEI KABUSHIKI KAISHA (JP) 2003-12-04 US disclosed
EP-1209150-A1 PROCESSES FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES Asahi Kasei Kabushiki Kaisha (JP) 2002-05-29 EP disclosed
EP-1174426-A1 METHOD FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES THROUGH AZIDES Asahi Kasei Kabushiki Kaisha (JP) 2002-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225289-A1 Process for the preparation of tricyclic amino alcohol derivatives ADH1A, ADH1C, OXER1 SLC1A3 520/4885SLC1A2 593/4885SLC1A1 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.